|Intersect's new sinusitis implant is like its Propel, above, but designed to be implanted without surgery.--Courtesy of Intersect ENT|
Company: Intersect ENT
Device: Nonsurgical sinus implant
Drug delivered: mometasone furoate steroid
Why it's important: Intersect ENT's sinus implants continue to make waves in the delivery device industry, the company having recently gained $30 million in Series D funding for its ongoing line of implants. The newest device in Intersect's arsenal, and one to watch despite its recent entry into clinical trials, can be implanted during a normal physician's office visit without surgery, an innovation that could potentially widen the market considerably. The other two implants, Propel and the Propel mini, must be placed by a surgeon, but have already been on the market since 2011.
To treat chronic sinusitis, Intersect ENT's implants release a steroid drug, mometasone furoate, which helps maintain the sinus opening for up to 30 days.
Intersect ENT has gained a ton of interest from financial players, and Medtronic ($MDT) has been one of the major investors in the quarter-sized implants as Intersect pushes for further commercial expansion.
Intersect ENT pulls in $30M Series D for sinusitis-implant sales push
Intersect ENT sees positive data on Propel from pivotal trial
Intersect ENT CEO discusses Propel implant
Intersect raises $30M for sinus treatment